Regulation of androgen receptor activity by tyrosine phosphorylation

被引:272
作者
Guo, Zhiyong
Dai, Bojie
Jiang, Tianyun
Xu, Kexin
Xie, Yingqiu
Kim, Oekyung
Nesheiwat, Issa
Kong, Xiangtian
Melamed, Jonathan
Handratta, Venkatesh D.
Njar, Vincent C. O.
Brodie, Angela M. H.
Yu, Li-Rong
Veenstra, Timothy D.
Chen, Hegang
Qiu, Yun [1 ]
机构
[1] Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA
[2] NYU, Sch Med, Dept Pathol, New York 10016, NY USA
[3] SAIC Frederick Inc, Lab Proteom & Analyt Technol, Natl Canc Inst Frederick, Ft Detrick, MD 21702 USA
[4] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA
关键词
D O I
10.1016/j.ccr.2006.08.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The androgen receptor (AR) is essential for the growth of prostate cancer cells. Here, we report that tyrosine phosphorylation of AR is induced by growth factors and elevated in hormone-refractory prostate tumors. Mutation of the major tyrosine phosphorylation site in AR significantly inhibits the growth of prostate cancer cells under androgen-depleted conditions. The Src tyrosine kinase appears to be responsible for phosphorylating AR, and there is a positive correlation of AR tyrosine phosphorylation with Src tyrosine kinase activity in human prostate tumors. Our data collectively suggest that growth factors and their downstream tyrosine kinases, which are elevated during hormone-ablation therapy, can induce tyrosine phosphorylation of AR and such modification may be important for prostate tumor growth under androgen-depleted conditions.
引用
收藏
页码:309 / 319
页数:11
相关论文
共 41 条
[1]   Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer [J].
Bartlett, JMS ;
Brawley, D ;
Grigor, K ;
Munro, AF ;
Dunne, B ;
Edwards, J .
JOURNAL OF PATHOLOGY, 2005, 205 (04) :522-529
[2]   REGULATION OF INTERLEUKIN-6, OSTEOCLASTOGENESIS, AND BONE MASS BY ANDROGENS THE ROLE OF THE ANDROGEN RECEPTOR [J].
BELLIDO, T ;
JILKA, RL ;
BOYCE, BF ;
GIRASOLE, G ;
BROXMEYER, H ;
DALRYMPLE, SA ;
MURRAY, R ;
MANOLAGAS, SC .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (06) :2886-2895
[3]   ANDROGEN-DEPENDENT GROWTH-REGULATION OF AND RELEASE OF SPECIFIC PROTEIN(S) BY THE ANDROGEN RECEPTOR CONTAINING HUMAN-PROSTATE TUMOR-CELL LINE LNCAP [J].
BERNS, EMJJ ;
DEBOER, W ;
MULDER, E .
PROSTATE, 1986, 9 (03) :247-259
[4]   Tyrosine kinase signalling in breast cancer - Epidermal growth factor receptor and c-Src interactions in breast cancer [J].
Biscardi, JS ;
Ishizawar, RC ;
Silva, CM ;
Parsons, SJ .
BREAST CANCER RESEARCH, 2000, 2 (03) :203-210
[5]   Molecular determinants of resistance to antiandrogen therapy [J].
Chen, CD ;
Welsbie, DS ;
Tran, C ;
Baek, SH ;
Chen, R ;
Vessella, R ;
Rosenfeld, MG ;
Sawyers, CL .
NATURE MEDICINE, 2004, 10 (01) :33-39
[6]   A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase [J].
Craft, N ;
Shostak, Y ;
Carey, M ;
Sawyers, CL .
NATURE MEDICINE, 1999, 5 (03) :280-285
[7]  
CULIG Z, 1994, CANCER RES, V54, P5474
[8]   Androgen receptor - an update of mechanisms of action in prostate cancer [J].
Culig, Z ;
Hobisch, A ;
Bartsch, G ;
Klocker, H .
UROLOGICAL RESEARCH, 2000, 28 (04) :211-219
[9]   Mechanisms of androgen-refractory prostate cancer. [J].
Debes, JD ;
Tindall, DJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15) :1488-1490
[10]   A history of prostate cancer treatment [J].
Denmeade, SR ;
Isaacs, JT .
NATURE REVIEWS CANCER, 2002, 2 (05) :389-396